Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer

Metastasis is the main cause of cancer mortality. One of the initiating events of cancer metastasis of epithelial tumors is epithelial-to-mesenchymal transition (EMT), during which cells dedifferentiate from a relatively rigid cell structure/morphology to a flexible and changeable structure/morphology often associated with mesenchymal cells. The presence of EMT in human epithelial tumors is reflected by the increased expression of genes and levels of proteins that are preferentially present in mesenchymal cells. The combined presence of these genes forms the basis of mesenchymal gene signatures, which are the foundation for classifying a mesenchymal subtype of tumors. Indeed, tumor classification schemes that use clustering analysis of large genomic characterizations, like The Cancer Genome Atlas (TCGA), have defined mesenchymal subtype in a number of cancer types, such as high-grade serous ovarian cancer and glioblastoma. However, recent analyses have shown that gene expression-based classifications of mesenchymal subtypes often do not associate with poor survival. This “paradox” can be ameliorated using integrated analysis that combines multiple data types. We recently found that integrating mRNA and microRNA (miRNA) data revealed an integrated mesenchymal subtype that is consistently associated with poor survival in multiple cohorts of patients with serous ovarian cancer. This network consists of 8 major miRNAs and 214 mRNAs. Among the 8 miRNAs, 4 are known to be regulators of EMT. This review provides a summary of these 8 miRNAs, which were associated with the integrated mesenchymal subtype of serous ovarian cancer.

[1]  Yanhong Shi,et al.  MicroRNAs: Small molecules with big roles in neurodevelopment and diseases , 2015, Experimental Neurology.

[2]  Wei Zhang,et al.  MiR‐506 inhibits multiple targets in the epithelial‐to‐mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer , 2015, The Journal of pathology.

[3]  Jun Ma,et al.  miR‐101 Acts as a Tumor Suppressor by Targeting Kruppel‐like Factor 6 in Glioblastoma Stem Cells , 2015, CNS neuroscience & therapeutics.

[4]  Leonid Peshkin,et al.  A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis , 2014, Cell.

[5]  Y. Zeng,et al.  MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of β-catenin signaling. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Fei-Fei Liu,et al.  MicroRNAs in nasopharyngeal carcinoma , 2014, Chinese journal of cancer.

[7]  R. Bamezai,et al.  MiR-101 Induces Senescence and Prevents Apoptosis in the Background of DNA Damage in MCF7 Cells , 2014, PloS one.

[8]  J. Haier,et al.  MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. , 2014, World journal of gastroenterology.

[9]  M. Barbareschi,et al.  MicroRNAs as lung cancer biomarkers. , 2014, World journal of clinical oncology.

[10]  Yuan Cao,et al.  Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway. , 2014, Molecular medicine reports.

[11]  Jeffrey K. Mito,et al.  MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. , 2014, The Journal of clinical investigation.

[12]  Jing Cai,et al.  miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer , 2014, Tumor Biology.

[13]  Xiao-jing Yang,et al.  A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells , 2014, Nucleic acids research.

[14]  O. Fortunato,et al.  Therapeutic Use of MicroRNAs in Lung Cancer , 2014, BioMed research international.

[15]  F. Huang,et al.  miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells. , 2014, International journal of clinical and experimental pathology.

[16]  Tadashi Kimura,et al.  The Role of MicroRNAs in Ovarian Cancer , 2014, BioMed research international.

[17]  T. Vondriska,et al.  Mesenchymal-endothelial-transition contributes to cardiac neovascularization , 2014, Nature.

[18]  Wenjing Pan,et al.  MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2 , 2014, Tumor Biology.

[19]  Liqiong Zeng,et al.  miR-101 Inhibits the G1-to-S Phase Transition of Cervical Cancer Cells by Targeting Fos , 2014, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[20]  N. Shen,et al.  Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation , 2014, Cell Death and Disease.

[21]  Jeffrey T. Chang,et al.  A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype , 2014, Breast Cancer Research.

[22]  Chaoqian Xu,et al.  miR-101 Promotes Breast Cancer Cell Apoptosis by Targeting Janus Kinase 2 , 2014, Cellular Physiology and Biochemistry.

[23]  A. Schrader,et al.  Clinical significance of epithelial-mesenchymal transition , 2014, Clinical and Translational Medicine.

[24]  Ilya Shmulevich,et al.  MiR‐506 suppresses proliferation and induces senescence by directly targeting the CDK4/6–FOXM1 axis in ovarian cancer , 2014, The Journal of pathology.

[25]  Weishan Zhang,et al.  MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. , 2014, Oncology reports.

[26]  Hiroko Oshima,et al.  MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1 , 2014, Gut.

[27]  J. Eun,et al.  MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma , 2014, Oncogene.

[28]  Hong-Fei Wu,et al.  A Ten-MicroRNA Signature Identified from a Genome-Wide MicroRNA Expression Profiling in Human Epithelial Ovarian Cancer , 2014, PloS one.

[29]  Fang Liu,et al.  miR-92a family and their target genes in tumorigenesis and metastasis. , 2014, Experimental cell research.

[30]  S. Shen,et al.  MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer , 2014, Clinical and Translational Oncology.

[31]  Wei Zhang,et al.  miR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma , 2014, Oncology reports.

[32]  J. Li,et al.  miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer , 2014, Oncogene.

[33]  Xiang-ming Ding,et al.  MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT) , 2014, Chinese journal of cancer.

[34]  A. Pertsemlidis,et al.  A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation , 2014, Oncotarget.

[35]  Yongjie Zhang,et al.  TGF-β upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1. , 2014, Molecular bioSystems.

[36]  Zhe Wang,et al.  Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation , 2014, Oncogene.

[37]  X. Chen,et al.  Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition , 2013, Oncogene.

[38]  Bo Hu,et al.  Noncoding RNAs in cancer and cancer stem cells , 2013, Chinese journal of cancer.

[39]  Eshel Ben-Jacob,et al.  MicroRNA-based regulation of epithelial–hybrid–mesenchymal fate determination , 2013, Proceedings of the National Academy of Sciences.

[40]  E. Li,et al.  Down‐regulated desmocollin‐2 promotes cell aggressiveness through redistributing adherens junctions and activating beta‐catenin signalling in oesophageal squamous cell carcinoma , 2013, The Journal of pathology.

[41]  Qinghe Zhang,et al.  Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. , 2013, Gene.

[42]  R. Postier,et al.  DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer , 2013, PloS one.

[43]  K. Kalland,et al.  MiR‐182 and miR‐203 induce mesenchymal to epithelial transition and self‐sufficiency of growth signals via repressing SNAI2 in prostate cells , 2013, International journal of cancer.

[44]  Xu Gao,et al.  MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. , 2013, Cancer letters.

[45]  Rende Guo,et al.  MicroRNA‐182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas , 2013, Journal of cellular biochemistry.

[46]  L. Qin,et al.  Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. G. de Herreros,et al.  PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation , 2013, PLoS genetics.

[48]  S. Shankar,et al.  NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. , 2013, Neuro-oncology.

[49]  Xiangyi Zheng,et al.  MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. , 2013, Biochemical and biophysical research communications.

[50]  W. Park,et al.  miR-506 Regulates Epithelial Mesenchymal Transition in Breast Cancer Cell Lines , 2013, PloS one.

[51]  Stephanie Ma,et al.  Clinical implications of microRNAs in liver cancer stem cells , 2013, Chinese journal of cancer.

[52]  M. Hou,et al.  Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. , 2013, Biochimica et biophysica acta.

[53]  Xiaofei Xu,et al.  The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation. , 2013, The international journal of biochemistry & cell biology.

[54]  Yang Wang,et al.  The role of miRNA-29 family in cancer. , 2013, European journal of cell biology.

[55]  E. Giovannetti,et al.  The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Sheila M. Reynolds,et al.  Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. , 2013, Cancer cell.

[57]  X. Wan,et al.  miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer , 2013, Medical Oncology.

[58]  Zhongjun Wu,et al.  miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. , 2013, Cellular signalling.

[59]  M. Fiorentino,et al.  Loss of miR‐101 expression promotes Wnt/β‐catenin signalling pathway activation and malignancy in colon cancer cells , 2013, The Journal of pathology.

[60]  J. Whitsett,et al.  Foxm1 transcription factor is required for lung fibrosis and epithelial‐to‐mesenchymal transition , 2013, The EMBO journal.

[61]  Sheng Tan,et al.  Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. , 2012, Cancer research.

[62]  Clare M. Isacke,et al.  MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes , 2012, PloS one.

[63]  Kai Fu,et al.  Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. , 2012, Cancer cell.

[64]  Zhaojian Liu,et al.  MiR‐182 overexpression in tumourigenesis of high‐grade serous ovarian carcinoma , 2012, The Journal of pathology.

[65]  Qiang Zhou,et al.  TSA Suppresses miR-106b-93-25 Cluster Expression through Downregulation of MYC and Inhibits Proliferation and Induces Apoptosis in Human EMC , 2012, PloS one.

[66]  Manuel A. S. Santos,et al.  Lack of microRNA‐101 causes E‐cadherin functional deregulation through EZH2 up‐regulation in intestinal gastric cancer , 2012, The Journal of pathology.

[67]  S. Greco,et al.  Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152 , 2012, Molecular Cancer.

[68]  Christopher G. Hill,et al.  The effects of MicroRNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated , 2012, BMC Medical Genomics.

[69]  Y. Toiyama,et al.  MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis , 2012, Gut.

[70]  S. Persad,et al.  Cadherin switch from E‐ to N‐cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail , 2012, The British journal of dermatology.

[71]  Yibo Gao,et al.  MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. , 2012, Biochemical and biophysical research communications.

[72]  A. D. Van den Abbeele,et al.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. , 2012, Blood.

[73]  Dimitris Anastassiou,et al.  A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma , 2012, PloS one.

[74]  Min Liu,et al.  MicroRNA‐182 targets cAMP‐responsive element‐binding protein 1 and suppresses cell growth in human gastric adenocarcinoma , 2012, The FEBS journal.

[75]  Kenichi Sugihara,et al.  Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters , 2012, Clinical Cancer Research.

[76]  Aamir Ahmad,et al.  Recent updates on the role of microRNAs in prostate cancer , 2012, Journal of Hematology & Oncology.

[77]  A. Fusco,et al.  Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. , 2012, The Journal of clinical endocrinology and metabolism.

[78]  Hongbing Shen,et al.  A Genetic Variant in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma , 2012, PloS one.

[79]  Y. Mizuguchi,et al.  Cooperation of p300 and PCAF in the Control of MicroRNA 200c/141 Transcription and Epithelial Characteristics , 2012, PloS one.

[80]  H. Long,et al.  Aberrant microRNAs expression in CD133+/CD326+ human lung adenocarcinoma initiating cells from A549 , 2012, Molecules and cells.

[81]  Stephen T Warren,et al.  Molecular mechanisms of fragile X syndrome: a twenty-year perspective. , 2012, Annual review of pathology.

[82]  T. Dønnem,et al.  MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer , 2012, PloS one.

[83]  H. Ford,et al.  The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer , 2012, Oncogene.

[84]  P. Muti,et al.  MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function , 2011, Cell Death and Differentiation.

[85]  Xin Lu,et al.  MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. , 2011, Oncology reports.

[86]  P. Vogt Cyclin Dependent Kinase , 2011 .

[87]  F. Luo,et al.  Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical significance. , 2011, Oncology reports.

[88]  Tanja Kunej,et al.  Epigenetic regulation of microRNAs in cancer: an integrated review of literature. , 2011, Mutation research.

[89]  L. De Cecco,et al.  Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients , 2011, Oncotarget.

[90]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[91]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[92]  R. Batchu,et al.  MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1 , 2011, Pharmaceutical Research.

[93]  B. Bao,et al.  Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. , 2011, Cancer letters.

[94]  Ying Xu,et al.  MicroRNA Expression and Regulation in Human Ovarian Carcinoma Cells by Luteinizing Hormone , 2011, PloS one.

[95]  B. Davidson,et al.  miRNA profiling along tumour progression in ovarian carcinoma , 2011, Journal of cellular and molecular medicine.

[96]  Ignacio Varela,et al.  Aging and chronic DNA damage response activate a regulatory pathway involving miR‐29 and p53 , 2011, The EMBO journal.

[97]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[98]  A. Gill,et al.  MicroRNA Profiling of Sporadic and Hereditary Medullary Thyroid Cancer Identifies Predictors of Nodal Metastasis, Prognosis, and Potential Therapeutic Targets , 2011, Clinical Cancer Research.

[99]  T. Brabletz,et al.  p53 spreads out further: suppression of EMT and stemness by activating miR-200c expression , 2011, Cell Research.

[100]  T. Luedde,et al.  Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis , 2011, Hepatology.

[101]  M. Hung,et al.  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[102]  M. Hung,et al.  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[103]  Zhaoli Chen,et al.  microRNA-92a Promotes Lymph Node Metastasis of Human Esophageal Squamous Cell Carcinoma via E-Cadherin* , 2010, The Journal of Biological Chemistry.

[104]  X. Wang,et al.  The clinical potential of microRNAs , 2010, Journal of hematology & oncology.

[105]  F. Ferrari,et al.  A MicroRNA Targeting Dicer for Metastasis Control , 2010, Cell.

[106]  Oliver Distler,et al.  MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. , 2010, Arthritis and rheumatism.

[107]  K. Wiman,et al.  Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells. , 2010, Carcinogenesis.

[108]  Sun Young Park,et al.  Epithelial–mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma , 2010, Cancer science.

[109]  F. Wuest,et al.  Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging. , 2010, Mini reviews in medicinal chemistry.

[110]  M. Loda,et al.  Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation , 2010, Science Signaling.

[111]  Ji Wan,et al.  Structure and activity of putative intronic miRNA promoters. , 2010, RNA.

[112]  X. Estivill,et al.  Design and evaluation of a panel of single-nucleotide polymorphisms in microRNA genomic regions for association studies in human disease , 2010, European Journal of Human Genetics.

[113]  Giuseppe Giannini,et al.  MiR‐128 up‐regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[114]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[115]  Alexey I Nesvizhskii,et al.  Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate Cancer* , 2009, Molecular & Cellular Proteomics.

[116]  M. Nieto,et al.  Inflammation and EMT: an alliance towards organ fibrosis and cancer progression , 2009, EMBO molecular medicine.

[117]  Zhiwei Wang,et al.  miR‐200 Regulates PDGF‐D‐Mediated Epithelial–Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells , 2009, Stem cells.

[118]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[119]  F. Sato,et al.  The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. , 2009, Gastroenterology.

[120]  D. Corcoran,et al.  Features of Mammalian microRNA Promoters Emerge from Polymerase II Chromatin Immunoprecipitation Data , 2009, PloS one.

[121]  C. Isella,et al.  A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis , 2009, Clinical & Experimental Metastasis.

[122]  Y. Fujii,et al.  microRNA expression profile in undifferentiated gastric cancer. , 2009, International journal of oncology.

[123]  Avner Friedman,et al.  MicroRNA regulation of a cancer network: Consequences of the feedback loops involving miR-17-92, E2F, and Myc , 2008, Proceedings of the National Academy of Sciences.

[124]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[125]  C. Croce,et al.  Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. , 2008, Cancer research.

[126]  M. F. Shannon,et al.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. , 2008, Cancer research.

[127]  G. Sonenshein,et al.  NF‐κB and epithelial to mesenchymal transition of cancer , 2008, Journal of cellular biochemistry.

[128]  Artemis G. Hatzigeorgiou,et al.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[129]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[130]  J. Mendell miRiad Roles for the miR-17-92 Cluster in Development and Disease , 2008, Cell.

[131]  D. Iliopoulos,et al.  E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. , 2008, Cancer cell.

[132]  Harrison W. Gabel,et al.  MicroRNA‐183 family conservation and ciliated neurosensory organ expression , 2008, Evolution & development.

[133]  Birgit Samans,et al.  MYCN regulates oncogenic MicroRNAs in neuroblastoma , 2007, International journal of cancer.

[134]  T. Golub,et al.  MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.

[135]  W. Lukiw,et al.  Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus , 2007, Neuroreport.

[136]  A. Bosserhoff,et al.  Expression of Dickkopf genes is strongly reduced in malignant melanoma , 2006, Oncogene.

[137]  Barbara A. Murphy,et al.  Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-κB Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma , 2006 .

[138]  Raghu Kalluri,et al.  The epithelial–mesenchymal transition: new insights in signaling, development, and disease , 2006, The Journal of cell biology.

[139]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[140]  A. Bosserhoff,et al.  Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma , 2006, Oncogene.

[141]  Yajun Yi,et al.  Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. , 2006, Cancer research.

[142]  P. Collas,et al.  Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. , 2005, Molecular biology of the cell.

[143]  D. Tarin,et al.  Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? , 2005, Cancer research.

[144]  D. Tarin,et al.  The fallacy of epithelial mesenchymal transition in neoplasia. , 2005, Cancer research.

[145]  Lena Smirnova,et al.  Regulation of miRNA expression during neural cell specification , 2005, The European journal of neuroscience.

[146]  D. Bartel,et al.  Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. , 2005, RNA.